Patricia Littel

发表

The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome.

T. Fleisher, D. Kuhns, D. McDermott, 2011, Blood.

WHIM Syndrome Caused by Waldenström’s Macroglobulinemia-Associated Mutation CXCR4L329fs

D. McDermott, H. Malech, P. Murphy, 2016, Journal of Clinical Immunology.

Effect of extended-release niacin on serum lipids and on endothelial function in adults with sickle cell anemia and low high-density lipoprotein cholesterol levels.

R. Cannon, H. Scoffone, R. Shamburek, 2013, The American journal of cardiology.

syndrome with the CXCR4 antagonist plerixafor A phase 1 clinical trial of long-term, low-dose treatment of WHIM

S. Pittaluga, D. Kuhns, D. McDermott, 2014 .

with WHIM syndrome The CXCR4 antagonist plerixafor corrects panleukopenia in patients

D. Kuhns, P. Murphy, R. Decastro, 2012 .

WHIM Syndrome Caused by Waldenström’s Macroglobulinemia-Associated Mutation CXCR4L329fs

D. McDermott, H. Malech, P. Murphy, 2016, Journal of Clinical Immunology.

A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor.

S. Pittaluga, T. Fleisher, D. Kuhns, 2014, Blood.

Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency

L. Notarangelo, J. Gray, D. Kuhns, 2016, Science Translational Medicine.

Exome sequencing study in a clinical research setting finds general acceptance of study returning secondary genomic findings with little decisional conflict

M. Lenardo, H. Su, L. Jamal, 2020, Journal of genetic counseling.

Infrared imaging of nitric oxide-mediated blood flow in human sickle cell disease.

A. Gorbach, R. Cannon, G. Kato, 2012, Microvascular research.

The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome.

T. Fleisher, D. Kuhns, H. Malech, 2011, Blood.